Who are High Dose Maolactin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Glatiramer acetate (Copaxone), injectable MS DMT, Ganoderma lucidum, Chloroquine prophylaxis, bee venom, β-1,3/1,6-D-glucan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/high-dose-maolactin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

High Dose Maolactin — Competitive Intelligence Brief

High Dose Maolactin (High Dose Maolactin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Infectious Diseases.

phase 3 Immunomodulator Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

High Dose Maolactin (High Dose Maolactin) — RDC Clinical Pty Ltd. High Dose Maolactin is an immunomodulatory agent that modulates the immune system to treat various conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
High Dose Maolactin TARGET	High Dose Maolactin	RDC Clinical Pty Ltd	phase 3	Immunomodulator
Glatiramer acetate (Copaxone)	Glatiramer acetate (Copaxone)	Federal University of São Paulo	marketed	Immunomodulator; disease-modifying therapy (DMT)	T cell receptor (indirect); myelin basic protein mimic
injectable MS DMT	injectable MS DMT	Biogen	marketed	Immunomodulator (disease-modifying therapy)
Ganoderma lucidum	Ganoderma lucidum	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Herbal/botanical immunomodulator
Chloroquine prophylaxis	Chloroquine prophylaxis	Radboud University Medical Center	marketed	Antimalarial; immunomodulator	Plasmodium falciparum heme detoxification pathway; toll-like receptors
bee venom	bee venom	Assistance Publique - Hôpitaux de Paris	marketed	Natural product immunomodulator
β-1,3/1,6-D-glucan	β-1,3/1,6-D-glucan	Al-Azhar University	marketed	Immunomodulator; biological response modifier	Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

Actavis Mid-Atlantic LLC · 1 drug in this class
Active Biotech AB · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Bayer · 1 drug in this class
Beijing Children's Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High Dose Maolactin — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-maolactin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab